Hot Pursuit     12-Feb-24
Zydus Lifesciences Ltd spurts 7.01%, up for third straight session
Zydus Lifesciences Ltd is quoting at Rs 861.45, up 7.01% on the day as on 12:49 IST on the NSE. The stock is up 82.72% in last one year as compared to a 21.78% gain in NIFTY and a 52.03% gain in the Nifty Pharma index.

Zydus Lifesciences Ltd rose for a third straight session today. The stock is quoting at Rs 861.45, up 7.01% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.65% on the day, quoting at 21641.95. The Sensex is at 71152.48, down 0.62%. Zydus Lifesciences Ltd has added around 20.17% in last one month.

Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has added around 6.45% in last one month and is currently quoting at 18617.1, up 0.18% on the day. The volume in the stock stood at 51.87 lakh shares today, compared to the daily average of 12.72 lakh shares in last one month.

The benchmark February futures contract for the stock is quoting at Rs 860.4, up 6.65% on the day. Zydus Lifesciences Ltd is up 82.72% in last one year as compared to a 21.78% gain in NIFTY and a 52.03% gain in the Nifty Pharma index.

The PE of the stock is 32.71 based on TTM earnings ending September 23.

Previous News
  Zydus receives USFDA approval for Zituvimet™ XR tablets
 ( Corporate News - 19-Jul-24   13:58 )
  Zydus completes acquisition of 50% stake in Sterling Biotech
 ( Corporate News - 30-Aug-24   11:21 )
  Zydus receives USFDA warning for injectables manufacturing unit at Jarod
 ( Corporate News - 30-Aug-24   14:49 )
  Zydus enters into exclusive licensing and supply agreement with Viwit
 ( Corporate News - 13-Sep-24   21:09 )
  Zydus Lifesciences Ltd drops for fifth straight session
 ( Hot Pursuit - 19-Sep-24   13:35 )
  Zydus Life gets USFDA nod for Zituvimet XR tablets
 ( Hot Pursuit - 19-Jul-24   11:53 )
  Zydus Lifesciences receives USFDA approval for Scopolamine Transdermal System
 ( Corporate News - 30-Aug-24   15:12 )
  Zydus Lifesciences receives USFDA approval for Lacosamide Tablets
 ( Corporate News - 16-Dec-23   11:43 )
  Zydus Life gains on USFDA nod for phase 2 clinical trial of ZYIL1
 ( Hot Pursuit - 18-Dec-23   09:22 )
  Zydus Life gets US FDA nod for seizure treatment drug Lacosamide
 ( Hot Pursuit - 16-Dec-23   15:37 )
  Zydus Life Jarod facility receives USFDA warning letter
 ( Hot Pursuit - 30-Aug-24   15:11 )
Other Stories
  UCO Bank’s total advances jump 19% YoY in Q2 FY25
  04-Oct-24   15:15
  Vakrangee Ltd leads losers in 'A' group
  04-Oct-24   15:00
  Kamdhenu Ventures Ltd leads losers in 'B' group
  04-Oct-24   14:45
  GRSE bags Rs 226-cr LoA from West Bengal Govt
  04-Oct-24   14:40
  Volumes soar at Avenue Supermarts Ltd counter
  04-Oct-24   14:30
  Real Estate stocks edge lower
  04-Oct-24   14:00
  Auto stocks edge lower
  04-Oct-24   14:00
  Utilties stocks edge lower
  04-Oct-24   14:00
  HDFC Bank Ltd down for fifth straight session
  04-Oct-24   13:35
  Power Grid Corporation of India Ltd down for fifth straight session
  04-Oct-24   13:35
Back Top